Therapies for the treatment of cancer and diseases associated with impaired phagocytosis
Patent Information
- Application Number
- JP2023551947
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-02-04
- Filing Date
- 2021-11-02
- Publication Date
- 2024-11-13
AI Technical Summary
Current therapies targeting the CD47-SIRPα interaction for cancer treatment have limited clinical and non-clinical efficacy due to defects in the phagocytic capacity of phagocytes, such as monocytes and macrophages, which can be attributed to nutritional status, insufficient innate immunity stimulation, polarization, and age-related senescence, leading to inadequate phagocytic dysfunction.
The use of phagocytosis activators like mitochondrial fission inhibitors (e.g., cilnidipine, P110, metformin, mdivi-1, berberine) to enhance the phagocytic activity of macrophages, either as monotherapy or in combination with additional agents like anti-CD47 or anti-SIRPα antibodies, to treat conditions associated with phagocytosis deficiencies, including cancer and other diseases.
Enhances phagocytic activity, improving the ability of phagocytes to eliminate cancer cells and induce adaptive immunity, thereby potentially increasing the effectiveness of cancer therapies and treating conditions such as neurodegenerative diseases, inflammatory diseases, and lysosomal diseases.
Smart Images

Figure 2022098642000001 
Figure 2022098642000002
Abstract
Description
[Technical Field]
[0001] Cross-reference of related applications This application claims priority to U.S. Provisional Application No. 63 / 109,111 filed 3 November 2020 and U.S. Provisional Application No. 63 / 145,681 filed 4 February 2021, the contents of which are incorporated herein by reference in their entirety. [Background technology]
[0002] CD47 is a widely expressed cell surface protein that binds to signal regulatory protein α (SIRPα) on macrophages, protecting healthy cells from macrophage phagocytosis. The interaction between CD47 and SIRPα is called the "don't eat me" signal. CD47 is often upregulated on cancer cells, which allows cancer cells to evade detection by the innate immune system. (Morissey and Vale, 2019, bioRxiv 752311; doi.org / 10.1101 / 752311). For example, blocking the interaction between CD47 and SIRPα with anti-CD47 or anti-SIRPα antibodies would weaken the "don't eat me" signal and activate the phagocytic function of macrophages and other phagocytic cells. Anti-CD47 and anti-SIRPα antibodies have generated promising clinical and nonclinical data in the field of oncology. However, a significant number of patients do not respond to therapies targeting the CD47-SIRPα interaction (see, for example, Advani et al., 2018, N Engl J Med. 379(18):1711-1721).
[0003] Beyond cancer, phagocytosis dysfunction is associated with other diseases, such as infections, neurodegenerative diseases, inflammation, and lysosomal disorders (e.g., Engelich et al., 2001, Clinical Infectious Diseases 33(12):2040-2048; Andrews and Sullivan, 2003, Clin Microbiol Rev. 16(4):597-621; Galloway et al., 2019, Front Immunol. 10:790; Kourtzelis et al., 2020, Front Immunol. 2020; 11: 553; Maderna and Godson, 2003, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1639(3):141-151; Marques and Saftig, 2019, Journal of Cell Science). See 132:jcs221739;Parkinson-Lawrence et al., 2010, Physiology 25:102-115).
[0004] There remains a need for novel therapies to treat diseases and conditions associated with cancer and phagocytosis insufficiency. [Overview of the project]
[0005] While not bound by theory, the limited clinical and nonclinical efficacy of CD47-SIRPα targeting therapy is thought to be related, at least in some cases, to impaired phagocytic capacity of phagocytic cells such as monocytes, macrophages, and microglia. This phagocytic impairment may be due to a variety of reasons, including nutritional status, insufficient stimulation of the innate immune system, phagocytic polarization, and aging-related changes in these cell lineages, including hematopoietic stem cells and monocytes. When phagocytic capacity is below optimal, blocking the interaction between CD47 and SIRPα may not be sufficient for phagocytic cells to eliminate cancer cells or induce the adaptive immune system to develop immunity against cancer cells.
[0006] While not bound by theory, it is further conceivable that enhancing the phagocytic activity of phagocytes with phagocytosis activators could improve outcomes in diseases and conditions associated with non-cancerous phagocytosis deficiency, such as infections, neurodegenerative diseases, inflammation, inflammatory diseases, lysosomal disorders, and musculoskeletal degenerative diseases like Duchenne muscular dystrophy (DMD).
[0007] Accordingly, in one aspect, the present disclosure provides methods of treating diseases and conditions associated with phagocytosis dysfunction, such as cancer, using an agent that activates phagocytosis, for example, a mitochondrial fission inhibitor such as cilnidipine, P110, metformin, mdivi-1, or berberine. The present disclosure is based, in part, on the finding that the mitochondrial fission inhibitor cilnidipine can enhance the phagocytic activity of macrophages. The phagocytosis activator may be administered as monotherapy, or alternatively, may be administered in combination with a further agent or a combination of multiple agents (e.g., an anti-CD47 antibody and / or an anti-SIRPα antibody). In some embodiments, the disease associated with phagocytosis dysfunction is cancer. In other embodiments, the disease associated with phagocytosis dysfunction is a non-cancer disease associated with phagocytic dysfunction, for example, an infectious disease, a neurodegenerative disease, an inflammatory disease, a lysosomal disease, or a musculoskeletal degenerative disease such as DMD.
[0008] Exemplary phagocytosis activators are described in Section 5.1 below and in certain Embodiments 2 to 89. Exemplary additional agents and combinations of agents that can be used in combination with one phagocytosis activator or in combination with a plurality of phagocytosis activators are described in Section 5.2 below and in certain Embodiments 111 to 148. Exemplary diseases associated with phagocytosis dysfunction are described in Section 5.4 below and in certain Embodiments 1 and 149 to 186.
[0009] In another aspect, the present disclosure provides a method of treating cancer (which may or may not be associated with phagocytosis deficiency) using a mitochondrial fission inhibitor such as cilnidipine, a cilnidipine derivative (e.g., as described in WO 2020 / 241638 pamphlet), P110, metformin, mdivi-1, or berberine. In some embodiments, the cancer has a KRAS mutation. A KRAS mutation can cause cancer cells to proliferate and spread in the body. Without being bound by theory, it is believed that mitochondrial fission inhibitors can inhibit proliferation signals caused by KRAS mutations in tumor cells.
[0010] The mitochondrial fission inhibitor may be administered as a monotherapy for cancer, or alternatively, may be administered as part of a combination therapy with, for example, an anti-PD1 or anti-PD-L1 antibody. In some embodiments, the combination therapy comprises a mitochondrial fission inhibitor, such as cilnidipine, administered in conjunction with a standard of care. Exemplary mitochondrial fission inhibitors are described in Section 5.1.1 below and in specific embodiments 5 to 54. Exemplary cancers that can be treated are described in Section 5.4.1 below and in specific embodiments 90 to 109.
[0011] In a further aspect, the present disclosure provides agents and combinations of agents for use in the methods described herein. The agents and combinations of agents may be present in a pharmaceutical composition. Exemplary agents, combinations of agents, and pharmaceutical compositions are described in Sections 5.1 to 5.3 below and in specific embodiments 187 to 237.
[0012] In yet another embodiment, the Disclosure provides pharmaceutical compositions comprising phagocytes having enhanced phagocytic activity. Phagocytes having enhanced phagocytic activity can be obtained by ex vivo treatment of phagocytes with a mitochondrial fission inhibitor, such as cilnidipine. Such pharmaceutical compositions can be used in methods for treating subjects having diseases or conditions associated with phagocytosis deficiency, such as cancer or other diseases or conditions disclosed herein. The phagocytes may be autologous to the subject being treated, or alternatively, the phagocytes may be homogeneous to the subject being treated. Exemplary pharmaceutical compositions comprising phagocytes having enhanced phagocytic activity, methods for producing them, and mitochondrial fission inhibitors for use in preparing such pharmaceutical compositions are described in Section 5.3 and Specific Embodiments 238-255 below. [Brief explanation of the drawing]
[0013] [Figure 1] This figure shows the enhancement of phagocytic activity in macrophages exposed to a DMSO vehicle or cilnidipine at concentrations of 0.3 μM, 1 μM, or 3 μM. The phagocytic rate is the percentage of cells that engulfed the indicated number of fluorescently labeled particles (1 or more particles, 2 or more particles, 3 or more particles, or 4 or more particles). [Figure 2] This figure shows the average fluorescence intensity derived from fluorescently labeled beads taken up by macrophages exposed to a DMSO vehicle or cilnidipine at concentrations of 0.3 μM, 1 μM, or 3 μM. [Figure 3] This figure shows the weight of the animals in Example 4. [Figure 4] This figure shows the results of rotorod latency for the animals in Example 4. The data is presented as mean value + SEM. [Figure 5]This figure shows the plasma LDH levels of animals in Example 4. Data are presented as mean + SEM; ### indicates p<0.001 by unpaired t-test for WT; * indicates p<0.05 by unpaired t-test for MDX-vehicle. [Figure 6] This figure shows the plasma CK levels of animals in Example 4. Data are presented as mean + SEM; ### indicates p<0.001 by unpaired t-test for WT; * indicates p<0.05 by unpaired t-test for MDX-vehicle. [Figure 7A] This figure shows the average body weight (Figure 7A) and the percentage change in body weight (Figure 7B) of the animals in Example 5. [Figure 7B] This figure shows the average body weight (Figure 7A) and the percentage change in body weight (Figure 7B) of the animals in Example 5. [Figure 8A] This figure shows the average tumor volume (Figure 8A) and the percentage of tumor volume inhibition (Figure 8B) of the animals in Example 5. [Figure 8B] This figure shows the average tumor volume (Figure 8A) and the percentage of tumor volume inhibition (Figure 8B) of the animals in Example 5. [Modes for carrying out the invention]
[0014] In one embodiment, the Disclosure provides a method for treating diseases and conditions associated with phagocytosis deficiency, such as cancer, using an agent that activates phagocytosis, either as monotherapy or alternatively, in combination with or with further agents (e.g., an anti-CD47 antibody and / or an anti-SIRPα antibody). Exemplary phagocytosis activators are described in Section 5.1. Exemplary further agents and combinations of agents are described in Section 5.2. Pharmaceutical compositions that can be used in the methods of the Disclosure are described in Section 5.3. Exemplary diseases associated with phagocytosis deficiency are described in Section 5.4.
[0015] In another embodiment, the Disclosure provides a method for treating cancer (which may or may not be related to phagocytosis failure) using mitochondrial fission inhibitors such as cilnidipine or cilnidipine derivatives. Examples of mitochondrial fission inhibitors are described in Section 5.1.1. Examples of cancers that can be treated are described in Section 5.4.1. In some embodiments, the method for treating cancer includes the step of administering an amount or combination of drugs effective in slowing the progression of the cancer in question (e.g., slowing the rate of tumor growth).
[0016] In yet another embodiment, the Disclosure provides a method for treating non-cancerous diseases associated with phagocytic dysfunction, such as infections, neurodegenerative diseases, inflammatory diseases, and lysosomal diseases, using mitochondrial fission inhibitors, such as cilnidipine or cilnidipine derivatives. Exemplary non-cancerous indications are described in Section 5.4.2. In some embodiments, a method for treating a non-cancerous disease may include the step of administering an effective amount of the drug or combination of drugs to improve one or more symptoms of the disease. In some embodiments, a method for treating a non-cancerous disease may include the step of administering an effective amount of the drug or combination of drugs to improve one or more biomarkers of the disease.
[0017] In further embodiments, this disclosure provides agents and combinations of agents for use in the methods described herein, as well as pharmaceutical compositions containing such agents. Exemplary agents, combinations of agents, and pharmaceutical compositions are described in Sections 5.1 to 5.3.
[0018] In some embodiments of the methods of this disclosure, the subjects have phagocytic dysfunction. Phagocytic dysfunction can be measured, for example, using an in vitro assay that measures phagocytic activity. Example 1 describes an in vitro assay that can be configured to measure the phagocytic activity of a subject (for example, subject macrophages and / or other types of phagocytes can be isolated and used in the assay described in Example 1, but in the absence of cilnidipine). The phagocytic activity of the subject phagocytes can be compared to a control phagocytic activity value obtained, for example, using phagocytes from a population of healthy subjects.
[0019] The subject treated by the method described herein is preferably a mammal, and most preferably a human.
[0020] 5.1. Phagocytosis Activators Various phagocytosis activators can be used in the methods of this disclosure. For example, the activator may be a mitochondrial fission inhibitor (e.g., a Drp1 inhibitor), a PGC1α activator, a PI3K-AKT-mTOR pathway inhibitor, or a single component or combination of components derived from the culture medium of lactate-releasing bacteria. Combinations of such agents can also be used (e.g., a combination of two or more mitochondrial fission inhibitors, a combination of a mitochondrial fission inhibitor and a PGC1α activator, a combination of a mitochondrial fission inhibitor and a PI3K-AKT-mTOR pathway inhibitor, etc.). Classifying phagocytosis activators as specific types of agents is for convenience, and it is understood that agents may have multiple mechanisms of action. Therefore, the methods of this disclosure that include the step of administering a specific agent to a subject are not limited to a specific mechanism of action.
[0021] 5.1.1. Mitochondrial fission inhibitors Mitochondria are organelles found in almost all eukaryotic cells and are primarily involved in ATP production as a result of oxidative phosphorylation occurring in the electron transport chain. Mitochondria undergo frequent fusion and fission, and abnormalities in this process are known to be associated with cancer. Mitochondrial fission is induced by the activation of Drp1, a GTP-binding protein. Cilnidipine, which works by blocking L-type and N-type calcium channels and has been used as a drug for treating hypertension, is also known to inhibit the formation of the Drp1-filamine complex, thereby inhibiting mitochondrial fission. Nishimura et al., 2018, Sci. Signal. 11(556): eaat5185. Example 1 of this disclosure shows that cilnidipine also enhances the phagocytotic activity of macrophages. Therefore, in some embodiments, phagocytosis activators or combinations of multiple phagocytosis activators include Drp-1 inhibitors such as cilnidipine or its derivatives.
[0022] Cilnidipine has the following structure:
[0023] [ka]
[0024] Exemplary cilnidipine derivatives are described in International Publication No. 2020 / 241638, the entirety of which is incorporated herein by reference.
[0025] In some embodiments, the phagocytosis activator is of formula (I):
[0026] [ka] The compound, or a pharmacologically acceptable salt thereof, or a solvate thereof. (In the formula: R 1is a phenyl compound substituted with 1 to 3 substituents, each substituent independently being NO2, NH2, OH, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl, wherein at least one substituent is NO2 or NH2; R 2 is H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl; R 3 is H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl; R 4 These are C1-C6 alkyl or C1-C6 haloalkyl; R 5 is phenyl or pyridinyl, where phenyl or pyridinyl is unsubstituted, or each substituent is independently substituted with 1 to 3 substituents which are NO2, NH2, OH, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl. (i) bond a exists and bonds b and c do not exist, or (ii) bonds b and c exist and bond a does not exist; A is NH if bond a is present, and N if bond b and bond c are present; m is an integer from 1 to 4; n is an integer from 1 to 3.
[0027] In some embodiments, the compound of formula (I) is something other than cilnidipine. Such a compound of formula (I) is an example of a cilnidipine derivative.
[0028] Further properties of the compound of formula (I) are described in the following specific embodiments 9 to 50.
[0029] In some embodiments, the compound of formula (I) is:
[0030] [ka] (referred to as "NS4-019" in International Publication No. 2020 / 241638), or a pharmacologically acceptable salt thereof or a solvate thereof.
[0031] In other embodiments, the compound of formula (I) is:
[0032] [ka] (referred to as "NS4-238" in International Publication No. 2020 / 241638), or its pharmacologically acceptable salts or solvates thereof.
[0033] In other embodiments, the compound of formula (I) is:
[0034] [ka] (referred to as "NS4-043" in International Publication No. 2020 / 241638), or its pharmacologically acceptable salts or solvates thereof.
[0035] In other embodiments, the compound of formula (I) is:
[0036] [ka] (referred to as "NS4-700" in International Publication No. 2020 / 241638), or its pharmacologically acceptable salts or solvates thereof.
[0037] In other embodiments, the compound of formula (I) is:
[0038] [ka] (referred to as "NS4-021" in International Publication No. 2020 / 241638), or its pharmacologically acceptable salts or solvates thereof.
[0039] In other embodiments, the compound of formula (I) is:
[0040] [ka] (referred to as "JYK-002" in International Publication No. 2020 / 241638), or its pharmacologically acceptable salts or solvates thereof.
[0041] In other embodiments, the compound of formula (I) is:
[0042] [ka] (referred to as "JYK-003" in International Publication No. 2020 / 241638), or its pharmacologically acceptable salts or solvates thereof.
[0043] In some embodiments, the compound of formula (I) is:
[0044] [ka] (referred to as "JYK-001" in International Publication No. 2020 / 241638), or its pharmacologically acceptable salts or solvates thereof.
[0045] In other embodiments, the compound of formula (I) is:
[0046] [ka] (referred to as "JYK-004" in International Publication No. 2020 / 241638), or its pharmacologically acceptable salts or solvates thereof.
[0047] Further mitochondrial fission inhibitors include P110 (YGRKKRRQRRRGGDLLPRGS-NH2; Qi et al., 2013, J Cell Sci, 126(Pt 3):789-802; U.S. Patent No. 10,245,297; see International Publication No. 2018 / 195491), metformin, mdivi-1, or berberine. Further mitochondrial fission inhibitors, including Drp1 inhibitors, are described in International Publication Nos. 2012 / 158624, 2016 / 130143, 2018 / 052891, and 2019 / 126179, the contents of which are incorporated herein by reference in their entirety.
[0048] 5.1.2. Further phagocytosis activators Further phagocytosis activators that can be used in the manner of this disclosure (for example, alone or in combination with the agents described in 5.1.1 and / or 5.1.2) include agents that activate Toll-like receptors (TLRs) (for example, by being agonists thereof), Dectin-1, mannose receptors, scavenger receptor A, CD14, CD36, opsonin receptors, or apoptotic body receptors.
[0049] TLR agonists activate TLRs, including, for example, TLR3, TLR4, or RIG1. Examples of TLR agonists include pathogen-associated molecular patterns (PAMPs) and their mimics. These microbial molecular markers may consist of proteins, carbohydrates, lipids, nucleic acids, and / or combinations thereof, as is known in the art, and may be internal or external. Examples include LPS, zymosan, peptidoglycan, flagellin, synthetic TLR2 agonists Pam3cys, Pam3CSK4, MALP-2, imiquimod, and CpG ODN.
[0050] TLR3 agonists include double-stranded RNAs such as poly(I:C), poly(AU), etc., in which case such nucleic acids typically have a size of at least about 10 bp, at least about 20 bp, or at least about 50 bp, and can have a high molecular weight of about 1 to about 20 kb, usually about 50 to 100 kb. Alternative TLR3 agonists can directly bind to proteins, for example, antibodies or small molecules that selectively bind to and activate TLR3. Other TLR3 agonists include retroviruses, such as retroviruses that have been engineered to lack the ability to integrate into the genome.
[0051] The TLR3, 4, 7 / 8, and 9 agonists include: 852A: a synthetic imidazoquinoline mimicking viral ssRNA; VTX-2337: a small molecule selective TLR8 agonist mimicking viral ssRNA; BCG: Mycobacterium bovis, the bacterium of Calmette-Guélain; CpG ODN: CpG oligodeoxynucleotide; Imiquimod: a synthetic imidazoquinoline mimicking viral ssRNA; LPS: lipopolysaccharide; MPL: monophosphoryl lipid A; polyI:C: polyriboinosine-polyribocytidylic acid; polyICLC: polyI:C-poly-I-lysine; reximod: a synthetic imidazoquinoline mimicking viral ssRNA.
[0052] Imiquimod is a synthetic imidazoquinoline that targets TLR7. 852A, a newer imidazoquinoline TLR7 agonist administered parenterally as monotherapy, has shown moderate clinical efficacy in disease stabilization as monotherapy. Regiquimod is an imidazoquinoline TLR7 / 8 agonist in humans.
[0053] CpGs are single-chain oligodeoxynucleotides (ODNs) characterized by motifs containing cytosine and guanine. Based on their immunological effects, CpG ODNs are classified into three distinct classes: CpG-A, potent stimulants of NK cells due to their IFN-α production effect on pDCs; CpG-B, moderate IFN-α inducers and enhancers of antigen-specific immune responses (upregulating costimulatory molecules on pDCs and B cells, inducing Th1 cytokine production, and stimulating antigen presentation by pDCs); and CpG-C, which combines the stimulating capacity of both CpG-A and CpG-B. CpG 7909 (PF-3512676, CpG type B and TLR9 agonist) has been evaluated in several tumor types, including renal cell carcinoma, glioblastoma, melanoma, cutaneous T-cell lymphoma, and non-Hodgkin lymphoma.
[0054] Polyriboinosine-polyribocytidylic acid (Poly-I:C) is a synthetic analog of viral dsRNA that stimulates endosomes (TLR3) and / or cytosolic melanoma differentiation-associated gene 5 (MDA5), resulting in increased production of type I IFN.
[0055] Lipid A molecules that target the TLR4 complex include monophosphoryl lipid A (MPL) and lipid A derivatives derived from Salmonella minnesota.
[0056] Dectin-1 agonists include beta-glucan, heat-sterilized Candida albicans, heat-sterilized Saccharomyces cerevisiae, whole glucan particles (WGP), and zymosan (a cell wall preparation of S. cerevisiae).
[0057] Mannose receptor activators include RP-182 (Jaynes et al., 2020, Science Translational Medicine 12(530):eaax6337).
[0058] Scavenger receptor A activators include low-endotoxin acetylated LDL (AcLDL) (Jozefowski et al., 2014, Innate Immun. 20(8):826-47).
[0059] CD14 activators include flavivirus NS1 protein, LPS, and oxPAPC (oxidized 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine).
[0060] CD36 activators include NKS-3 (see International Publication No. 2019 / 229005) and the CD36 agonist peptide ABT-510.
[0061] Opsonin receptor activators include aggregated C3 protein and aggregated C3b protein.
[0062] Further examples of phagocytosis activators include 1,3-beta-glucan, mannan, lipopolysaccharide (LPS), lipoteichoic acid, lipopolysaccharide-binding protein, Plasmodium falciparum-infected red blood cells, IgG, IgA, IgE, and phosphatidylserine. In some embodiments, the phagocytosis activator or combination of multiple phagocytosis activators includes 1,3-beta-glucan. In some embodiments, the phagocytosis activator or combination of multiple phagocytosis activators includes mannan. In some embodiments, the phagocytosis activator or combination of multiple phagocytosis activators includes lipopolysaccharide (LPS). In some embodiments, the phagocytosis activator or combination of multiple phagocytosis activators includes lipoteichoic acid. In some embodiments, the phagocytosis activator or combination of multiple phagocytosis activators includes lipopolysaccharide-binding protein. In some embodiments, the phagocytosis activator or combination of multiple phagocytosis activators contains Plasmodium falciparum-infected red blood cells. In some embodiments, the phagocytosis activator or combination of multiple phagocytosis activators contains IgG. In some embodiments, the phagocytosis activator or combination of multiple phagocytosis activators contains IgA. In some embodiments, the phagocytosis activator or combination of multiple phagocytosis activators contains IgE. In some embodiments, the phagocytosis activator or combination of multiple phagocytosis activators contains phosphatidylserine.
[0063] In further embodiments, phagocytosis activators include agents that activate PPARG coactivator 1 alpha (PGC1α). Exemplary PGC1α activators include metformin, ZLN005 (Zhang et al., 2013, Diabetes. 62(4):1297-307), and mogroside VI B (Niu et al., 2017, J Nat Prod. 80(5):1428-1435). Further agents that enhance PGC1α activity include peroxisome proliferator-activated receptor (PPAR)-gamma agonists, AMPK activators, and sirtuin activators. Exemplary PPAR-γ agonists include thiazolidinedione (TZD), allegritazar, falgritazar, mulagritazal, and tesagritazal. Exemplary TZDs include pioglitazone, rosiglitazone, riboglitazone, and troglitazone. Exemplary AMPK activators include 5-aminoimidazole-4-carboxamidoripbonucleotide (AICAR). Exemplary sirtuin activators include resveratrol, SRT1720, SRT2104, SRT2183, SRT1460, and combinations thereof.
[0064] In further embodiments, the phagocytosis activator or combination of multiple phagocytosis activators includes agents that inhibit the PI3K-AKT-mTOR pathway. The PI3K-AKT-mTOR pathway is an important intracellular signaling pathway for regulating macrophage phagocytic capacity (Weichhart et al., 2015, Nat Rev Immunol. 15(10): 599-61). Agents that inhibit the PI3K-AKT-mTOR pathway may be, for example, agents that inhibit PI3K, agents that inhibit AKT, or agents that inhibit mTOR. Exemplary PI3K inhibitors include pictilisib, buparlisib, idelalisib, copanlisib, duvelisib, gedatricib, and apitricib. Exemplary AKT inhibitors include ipatasertib, MK-2206, and ARQ-092. Examples of mTOR inhibitors include rapamycin, everolimus, 32-deoxorapamycin, 16-pento-2-inyloxy-32-deoxorapamycin, 16-pento-2-ylyloxy-32(S)-dihydro-rapamycin, 16-pento-2-ylyloxy-32(S)-dihydro-40-O-(2-hydroxyethyl)-rapamycin, rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779), U.S. Patent No. 5,36 Examples include 40-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]-rapamycin or a pharmaceutically acceptable salt thereof, ABT578, as disclosed in Specification No. 2,718, or 40-(tetrazolyl)-rapamycin, 40-epi-(tetrazolyl)-rapamycin, as disclosed in, for example, International Publication No. 99 / 15530, or rapamycin analogs, such as AP23573, as disclosed in, for example, International Publication No. 98 / 02441 and International Publication No. 01 / 14387.
[0065] In further embodiments, the phagocytosis activator includes one or more bacterial strains, e.g., one or more probiotic strains and / or bacterial culture media, e.g., components or combinations of components derived from probiotic culture media. Probiotic bacteria can activate phagocytosis. See, for example, Gorska et al., 2019, Curr Microbiol. 76(8):939-949. The bacteria may include, for example, lactic acid-producing bacteria. In some embodiments, the phagocytosis activator includes components or combinations of components of cell-free extracts derived from lactic acid-releasing bacterial culture media. Examples of lactic acid-releasing bacteria include the genera Lactobacillus, Leuconostoc, Pediococcus, Lactococcus, and Streptococcus, Aerococcus, Carnobacterium, Enterococcus, Oenococcus, Sporolactobacillus, Tetragenococcus, Vagococcus, and Weissella. In some embodiments, the lactic acid bacteria include species of the genus Bifidobacterium (Bifidobacterium sp.) and / or the genus Lactobacillus, such as L. acidophilus. Exemplary bacterial formulations are described in International Publication No. 2016 / 196605 and International Publication No. 2004 / 087178, the contents of which are incorporated herein by reference in their entirety. Formulations containing live bacteria may be administered by any suitable route, for example, orally, intravenously, or intratumorally.
[0066] 5.2. Second drug and combination of second drugs In some embodiments, a phagocytosis activator or a combination of multiple phagocytosis activators is administered in combination with one or more additional agents, for example, one or more standard treatments for the disease in question, or one or more additional agents described herein.
[0067] As used herein, “administered in combination” means that two (or more) different treatments are delivered to the subject during the course of the subject’s suffering due to the disorder, for example, after the subject is diagnosed with the disorder and before the disorder is cured or eliminated, or before the treatment is discontinued for any other reason. In some embodiments, the delivery of one treatment is still occurring when the delivery of a second treatment is initiated, resulting in an overlap in administration. Such may be called “simultaneous” or “concurrent delivery.” The term “concurrently” is not limited to the administration of multiple therapies (e.g., a phagocytosis activator and a further drug) at exactly the same time, but rather means that a pharmaceutical composition containing one drug is administered to the subject in a certain order and within a certain time interval such that the drug can act together with the further drug to provide a better effect than if they were otherwise administered. For example, each drug in a combination may be administered to the subject at the same time or at different times in any order; however, if they are not administered at the same time, they must be administered close enough in time to produce the desired therapeutic effect.
[0068] A method for treating cancer disclosed herein may include the step of administering a phagocytosis activator in combination with a CD47 inhibitor, e.g., an anti-CD47 antibody and / or a SIRPα inhibitor, e.g., an anti-SIRPα antibody.
[0069] Phagocytosis activators, such as mitochondrial fission inhibitors like cilnidipine and cilnidipine derivatives, as described in Section 5.1.1, may be used in combination with one or more additional anticancer therapies, such as standard treatment, while a particular cancer is being treated. For example, a subject with pancreatic cancer may be treated with cilnidipine, its salts, or solvates thereof in combination with gemcitabine.
[0070] 5.2.1. CD47 inhibitors CD47 inhibitors include anti-CD47 antibodies, such as AO-176 (see Puro et al., 2020, Molecular Cancer Therapeutics 19(3):835-846), maglorimab (also known as hu5F9-G4; Gilead), CC-90002 (Celgene; see Zeidan et al., 2019, Blood 134 (Supplement_1): 1320), IBI-188 (Innovent Biologies), SHR-1063 (Gao et al., 2019, J Pharm Biomed Anal 175:112792), and AMMS4-G4 (Zeng, et al. 2016, Oncotarget 7: 83040-50). Further examples of anti-CD47 antibodies include clones B6H12, 5F9, 886, and C3 (e.g., described in International Publication No. 2011 / 143624). Further anti-CD47 antibodies are described in International Publication Nos. 2015 / 191861 and International Publication Nos. 2016 / 081423. Anti-CD47 antibodies can be, for example, fully humanized, humanized, or chimeric versions of such antibodies. Humanized antibodies (e.g., hu5F9-G4) are particularly useful for in vivo applications in humans due to their low antigenicity.
[0071] Further CD47 inhibitors include TTI-621, a recombinant fusion protein composed of the human SIRPα N-terminus linked to the Fc of IgG1; ALX148, another SIRPα-Fc fusion protein (ALX Oncology); and CV1, a SIRPα variant with high affinity for CD47 that competes with endogenous SIRPα for CD47 binding (Huang et al., 2017, J Thorac Dis. 2017 Feb; 9(2): E168-E174).
[0072] 5.2.2. SIRPα inhibitors SIRPα inhibitors include anti-SIRPα antibodies, such as KWAR23 (Ring et al., 2017, Proc Natl Acad Sci 114(49):E10578-E10585), CC-95251 (Celgene), and BI 765063 (also known as OSE-172; OSE Immunotherapeutics). Further examples of anti-SIRPα antibodies are described in International Publication No. 2019 / 023347, International Publication No. 2013 / 056352, and International Publication No. 2018 / 190719.
[0073] In some embodiments, the SIRPα inhibitor is a soluble CD47 polypeptide, such as that described in U.S. Patent Application Publication 2010 / 0239579. In certain embodiments, the soluble CD47 polypeptide comprises the extracellular domain of CD47 (e.g., signal peptide; SEQ ID NO: 2 in International Publication Brochure 2016 / 118754), and as a result, the extracellular portion of CD47 is typically 142 amino acids long and has the amino acid sequence described in SEQ ID NO: 3 in International Publication Brochure 2016 / 118754. The soluble CD47 polypeptides described herein also include CD47 extracellular domain variants comprising at least 65%–75%, 75%–80%, 80–85%, 85%–90%, or 95%–99% (or any percentage of identity between 65% and 100% not specifically enumerated) of the amino acid sequence, such variants retain the ability to bind to SIRPα without stimulating SIRPα signaling.
[0074] 5.2.3. Further medications The phagocytosis activators described herein, such as mitochondrial fission inhibitors, may be administered as monotherapy. Alternatively, the phagocytosis activator may be administered to the subject in conjunction with further agents or combinations of agents to treat the disease of interest. For example, a subject with cancer may be administered one or more chemotherapeutic agents and / or one or more immunotherapeutic agents, such as an anti-PD1 antibody (e.g., cemiprimab, nivolumab, or pembrolizumab) and / or an anti-PD-L1 antibody (e.g., avelumab, durvalumab, or atezolizumab). In some embodiments, the further agents or combinations of agents include standard treatment for the disease of interest.
[0075] For patients with pancreatic cancer, additional drugs or drug combinations may include, for example, gemcitabine and / or paclitaxel.
[0076] For patients with lung adenocarcinoma, additional drugs or combinations of drugs may include, for example, cisplatin and / or carboplatin.
[0077] For patients with colorectal cancer, additional drugs or combinations of drugs may include, for example, cetuximab and / or panitumumab.
[0078] 5.3. Pharmaceutical Compositions This disclosure provides pharmaceutical compositions comprising one or more agents as described herein. The pharmaceutical compositions can be used in the manner of this disclosure. For example, pharmaceutical compositions comprising agents as described herein, such as those described in Sections 5.1 and 5.2, including their subparts, can be formulated according to techniques known in the art. For example, the pharmaceuticals described herein may be in the form of, for example, lyophilized powder, slurry, aqueous solution, lotion, or suspension, and may be combined with one or more carriers, excipients, stabilizers, or combinations thereof (e.g., Hardman et al., 2001, Goodman and Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, NY; Gennaro, 2000, Remington: The Science and Practice of Pharmacy, Lippincott, Williams, and Wilkins, New York, NY; Avis, et al. (eds.), 1993, Pharmaceutical Dosage Forms: General Medications, Marcel Dekker, NY; Lieberman, et al. (eds.), 1990, Pharmaceutical Dosage Forms: Tablets, Marcel Dekker, NY; Lieberman, et al. (eds.), 1990, Pharmaceutical Dosage Forms: Disperse Systems, Marcel See Dekker, NY; Weiner and Kotkoskie, 2000, Excipient Toxicity and Safety, Marcel Dekker, Inc., New York, NY.
[0079] In one embodiment, the present disclosure provides a pharmaceutical composition comprising a phagocytosis activator and / or further agents or combinations of further agents as described herein, as well as a pharmacodynamically acceptable diluent, carrier, or excipient.
[0080] The content of phagocytosis activators and / or additional agents or combinations of additional agents in the pharmaceutical composition can be selected as appropriate and is generally in the range of 0.01 to 100% by weight (for example, 1% to 99% by weight, 1% to 90% by weight, 5% to 80% by weight, 10% to 75% by weight, or 15% to 50% by weight of the pharmaceutical composition, or any weight percentage range determined by any two of the aforementioned values).
[0081] Phagocytosis activators (e.g., mitochondrial fission inhibitors) and / or additional agents or combinations of agents can be formulated into pharmaceutical compositions comprising one or more agents designed to target the delivery of the phagocytosis activator and / or additional agents or combinations of agents to the tumor microenvironment and / or phagocytes. For example, an agent or combination of agents can be formulated with bile acids and / or bile acid derivatives, such as ursodeoxycholic acid. Such formulations can be used to enhance the delivery of agents, for example, hydrophobic small molecules that are orally available. See Lozano et al., 2015, J Control Release 216:93-102; Mooranian et al., 2020, Sci Rep 10:106; Pavlovic et al., 2018, Front. Pharmacol. 9:1283; and U.S. Patent No. 10,765,751, the contents of which are incorporated herein by reference in their entirety.
[0082] In a further embodiment, the disclosure provides a pharmaceutical composition comprising phagocytes (e.g., monocytes, macrophages, neutrophils, dendritic cells, mast cells, or any combination thereof) having enhanced phagocytic activity. The enhanced phagocytic activity can be measured, for example, as described in Example 1. The pharmaceutical composition comprising phagocytes may, for example, contain a population of phagocytes and one or more further components, such as buffers or cell culture media.
[0083] Phagocytes having enhanced phagocytic activity can be obtained by ex vivo treatment of phagocytes with a mitochondrial fission inhibitor, such as cilnidipine and / or another mitochondrial fission inhibitor as described in Section 5.1.1. Such pharmaceutical compositions can be used in methods to treat subjects having diseases or conditions associated with phagocytosis deficiency, such as cancer or other diseases or conditions disclosed in Section 5.4. The phagocytes may be autologous to the subject being treated, or alternatively, allogeneic to the subject being treated.
[0084] The compositions of this disclosure may also be administered via one or more routes of administration using one or more of the various methods known in the art. As will be understood by those skilled in the art, the route and / or mode of administration will vary depending on the desired outcome. Predetermined routes of administration include, for example, intravenous, intramuscular, intradermal, intraperitoneal, subcutaneous, spinal, or other common routes of administration, such as by injection or infusion. Common administration may refer to modes of administration other than enteral and topical administration, usually by injection, and common administration includes, but is not limited to, intravenous, intramuscular, intra-arterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subepidermal, intra-articular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal, intratumoral, peritumoral, and intralymphatic injections and infusions. Alternatively, the compositions of this disclosure may be administered via uncommon routes of administration, such as topical, epidermal, or mucosal routes, for example, intranasal, oral, vaginal, rectal, sublingual, or topical.
[0085] In another aspect, the Disclosure provides the use of the agents disclosed herein, for example, cilnidipine or a pharmacoacceptable salt thereof or a solvate thereof, in the manufacture of a medicament for treating a disease or condition disclosed herein, for example, pancreatic cancer or DMD, which may optionally be formulated for administration as monotherapy or as part of a combination therapy regimen with a second agent, for example, as described herein.
[0086] 5.4. Diseases and conditions associated with cancer and phagocytosis failure 5.4.1. Cancer Cancers that can be treated according to the methods of this disclosure include hematological cancers and solid tumors. Exemplary cancers include pancreatic cancer (e.g., pancreatic ductal adenocarcinoma), lung cancer, small cell lung cancer or non-small cell lung cancer, e.g., lung adenocarcinoma, colorectal cancer, melanoma (e.g., with BRAF mutation), leukemia, e.g., acute myeloid leukemia or acute lymphoblastic leukemia, lymphoma, e.g., non-Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), myeloma, e.g., multiple myeloma, leiomyosarcoma, breast cancer, liver cancer, osteosarcoma, and head and neck cancers. In some embodiments, the subject has acute myeloid leukemia, lymphoma, non-Hodgkin lymphoma, or DLBCL.
[0087] In some embodiments, cancer has KRAS mutations. KRAS is a protein involved in cell signaling pathways that control cell proliferation, cell maturation, and cell death. Mutations in the KRAS gene have been found in certain types of cancer, including non-small cell lung cancer (NSCLC), colorectal cancer, lung cancer, and pancreatic cancer. These mutations may drive cancer cells to proliferate and spread throughout the body.
[0088] While not bound by theory, it is thought that deactivation of Drp1 by mitochondrial fission inhibitors such as cilnidipine can inhibit the proliferation signaling induced by KRAS mutations in tumor cells. Furthermore, Drp1 inhibition is thought to induce a metabolic shift from aerobic glycolysis to fatty acid oxidation, reducing oxidative stress in the tumor microenvironment, thereby facilitating CD8+ T cell infiltration into the tumor and / or increasing the persistence of T cells in the tumor microenvironment. Again, while not bound by theory, it is thought that this metabolic shift restores the phagocytic capacity of macrophages and natural killer cells in the tumor microenvironment, thereby facilitating tumor depletion and / or T cell priming / activation.
[0089] In some embodiments, the disclosure provides cilnidipine or a pharmacoacceptable salt thereof or a solvate thereof for use in methods of treating pancreatic cancer, such as pancreatic ductal adenocarcinoma. In some embodiments, cilnidipine or a pharmacoacceptable salt thereof or a solvate thereof is administered orally. In some embodiments, cilnidipine or a pharmacoacceptable salt thereof or a solvate thereof is administered as monotherapy. In other embodiments, cilnidipine or a pharmacoacceptable salt thereof or a solvate thereof is administered in combination with one or more further agents, such as gemcitabine (e.g., intravenously). In some embodiments, the amount of cilnidipine or a pharmacoacceptable salt thereof or a solvate thereof administered as monotherapy is an amount effective in slowing tumor growth in the subject. In some embodiments, when cilnidipine or a pharmacoacceptable salt thereof or a solvate thereof is administered in combination with gemcitabine, the amounts of cilnidipine and gemcitabine are effective together in slowing tumor growth in the subject. In some embodiments, the amounts of cilnidipine and gemcitabine are more effective together in slowing tumor growth in the subject than when administered individually.
[0090] 5.4.2. Diseases and conditions associated with non-cancerous phagocytosis. Phagocytosis dysfunction is associated with several diseases and conditions, such as infections, neurodegenerative diseases, inflammation, inflammatory diseases, and lysosomal disorders (e.g., Engelich et al., 2001, Clinical Infectious Diseases 33(12):2040-2048; Andrews and Sullivan, 2003, Clin Microbiol Rev. 16(4):597-621; Galloway et al., 2019, Front Immunol. 10:790; Kourtzelis et al., 2020, Front Immunol. 2020; 11: 553; Maderna and Godson, 2003, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1639(3):141-151; Abdolmakeki et al., 2018, Front Immunol. See 9:1645; Marques and Saftig, 2019, Journal of Cell Science 132:jcs221739). Phagocytosis also plays a role in musculoskeletal degenerative diseases such as Duchenne muscular dystrophy (DMD) (see, for example, Rosenberg et al., 2015, Sci Transl Med. 7(299):299rv4).
[0091] Infectious diseases include illnesses caused by bacteria (e.g., streptococcal infections), viruses (e.g., influenza, hepatitis B, hepatitis C, HIV), fungi (e.g., yeast infections), or parasites (e.g., malaria). Neurodegenerative diseases include Alzheimer's disease (AD), progressive supranuclear palsy (PSP) and other dementias, Parkinson's disease (PD), Nasu-Hakola disease, prion diseases, amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, Huntington's disease, Lewy body dementia, adrenoleukodystrophy (ALD), and spinal muscular atrophy. Exemplary inflammatory diseases include systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and autoimmune diseases such as autoimmune lymphoproliferative syndrome (ALPS). Lysosomal storage disorders include Gaucher disease, Fabry disease, Niemann-Pick disease, Hunter syndrome, glycogen storage disease type II (Pompe disease), and Tay-Sachs disease. Musculoskeletal degenerative diseases include muscular dystrophy such as DMD. Therefore, in some embodiments, subjects treated according to the methods of this disclosure have non-cancerous diseases as described herein.
[0092] In some embodiments, this disclosure provides cilnidipine or a pharmacoacceptable salt thereof or a solvate thereof for use in the target method of DMD. In some embodiments, cilnidipine or a pharmacoacceptable salt thereof or a solvate thereof is administered orally. In some embodiments, cilnidipine or a pharmacoacceptable salt thereof or a solvate thereof is administered as monotherapy. In some embodiments, the amount of cilnidipine or a pharmacoacceptable salt thereof or a solvate thereof administered is an amount effective in lowering plasma creatinine kinase (CK) levels and / or lactose dehydrogenase (LDH) levels. [Examples]
[0093] 6. Examples [Example 1] 6.1 In vitro study to evaluate the effect of cilnidipine on macrophage-mediated phagocytosis The effect of cilnidipine on macrophage-mediated phagocytosis was evaluated in vitro using the J774.1 mouse macrophage cell line. Cells were placed in 2 × 10⁶ well plates of 48-well plates. 5 Cells were seeded in 200 μL wells and cultured for 24 hours at 37°C under 5% CO2 in DMEM medium containing 10% FBS and antibiotics. The cells were washed once and then incubated for 20 hours with cilnidipine at concentrations of 0.3 μM, 1 μM, or 3 μM, or with DMSO (vehicle).
[0094] PE-labeled polystyrene beads (Fluoresbrite® Polychromatic Red Microspheres 2.0 μm) 4 × 10 6 The level of phagocytosis was assessed by adding 10 μL of DMEM medium containing PE-labeled beads to the cells and culturing them for 2.5 hours. The cells were then washed three times with PBS and harvested. The level of phagocytic activity was assessed by flow cytometry by measuring the amount of fluorescence signal derived from PE-labeled beads taken up by the cells, in which cells treated with 0.1% DMSO were used as a negative control. The percentage of cells phagocytosing one or more, two or more, three or more, and four or more particles was measured.
[0095] As shown in Figure 1, cilnidipine enhanced macrophage phagocytic activity in a dose-dependent manner. The average fluorescence intensity for each cilnidipine dose is shown in Figure 2.
[0096] [Example 2] 6.2. Evaluation of the antiproliferative effect of cilnidipine on cancer cell lines in vitro The effects of cilnidipine on cell proliferation in eight cancer cell lines will be evaluated. Three melanoma cell lines, two of which contain B-Raf mutations: A375(V600E) and SK-MEL-28(V600E), and one melanoma cell line possessing wild-type B-Raf and MeWo, will be included. In addition, five pancreatic cancer cell lines will be included, four of which contain KRAS mutations (AsPC-1(G12D), Capan-1(G12V), KP4(M188V, G12D), and MIAPaCa-2(G12C)), and one pancreatic cancer cell line possessing wild-type KRAS and BxPC-3.
[0097] Treatment of pancreatic cancer and melanoma cell lines with cilnidipine has an antiproliferative effect on the cell lines.
[0098] [Example 3] 6.3. In vivo evaluation of the antitumor effect of cilnidipine. The in vivo antitumor effect of cilnidipine will be evaluated in MC38 tumor-carrying C57BL / 6 mice. Five-week-old or seven-week-old C57BL / 6 mice will be maintained under specific pathogen-free (SPF) conditions. 5 × 10⁶ mice will be given 5 × 10⁶ doses. 5 Individual MC38 cells, a mouse colon adenocarcinoma cell line, were subcutaneously injected, and the tumors were treated with cilnidipine on days 10 and 14 after inoculation. Tumor volume was measured at various time points.
[0099] Treatment of mice with cilnidipine reduces tumor growth compared to control mice.
[0100] [Example 4] 6.4. In vivo evaluation of cilnidipine in the DMD model The effects of cilnidipine and its derivative NS4-043 were evaluated in the mdx mouse model of Duchenne muscular dystrophy (DMD). The mdx mouse has a point mutation in its DMD gene, in which the amino acid encoding glutamine is changed to a stop codon, leading to the production of small, non-functional dystrophin proteins in muscle cells. Table 1 shows the results of this study.
[0101] [Table 1] As shown, the treatment groups included cilnidipine, NS4-043, idebenone (positive control), and vehicle.
[0102] Animals were administered vehicle, idebenone, or cilnidipine once daily from day 0 to day 20 of the study.
[0103] Mice were evaluated by rotarod testing on days 19 and 20 of the study. Body weight was measured throughout the study period. Two biomarkers for DMD, creatinine kinase (CK) and lactose dehydrogenase (LDH), were measured on day 21.
[0104] No significant effect on body weight was observed in any of the treatment groups (Figure 3; data for NS4-043 are not shown). Latency (time until fall) in the rotarod test was reduced in mdx mice (all groups) compared to wild-type mice, but the reduction was not statistically significant in any group (Figure 4; data for NS4-043 are not shown). LDH was significantly elevated in the plasma of mdx mice compared to wild-type mice. Both cilnidipine and idebenone significantly reduced plasma LDH (Figure 5). NS4-043 did not significantly reduce plasma LDH in this study (data not shown), which may be due to insufficient exposure to the drug (medication). CK was significantly elevated in the plasma of mdx mice compared to wild-type mice. Surprisingly, cilnidipine, not idebenone, significantly suppressed plasma CK (Figure 6). Plasma CK levels in animals treated with NS4-043 were similar to those in animals treated with idebenone (data not shown). Therefore, this study provides justification for the use of cilnidipine and cilnidipine derivatives such as NS4-043 as treatments for DMD.
[0105] [Example 5] 6.5. In Vivo Evaluation of Cilnidipine in Combination with Cilnidipine and Gemcitabine in Pancreatic Cancer Model A study on the in vivo therapeutic efficacy of cilnidipine as a single agent or in combination with gemcitabine in the treatment of a subcutaneous Capan-1 pancreatic cancer xenograft model in female BALB / c nude mice was conducted.
[0106] 6.5.1 Materials and Methods 6.5.1.1. Animals Female BALB / c nude mice aged 7 to 9 weeks were used in the study.
[0107] 6.5.1.2. Study Design The study included 6 treatment groups as shown in Table 2.
[0108]
Table 2
[0109] 6.5.1.3. Study Methods The study included 6 treatment groups as shown in Table 2.
[0110] 6.5.1.3.1. Cell Culture Capan-1 human pancreatic ductal adenocarcinoma cells were cultured in IMEM medium containing 20% FBS at 37°C and 5% CO₂ in an air atmosphere.
[0111] 6.5.1.3.2. Tumor Inoculation Tumor cells (5×10 6 cells) in 0.1 ml of PBS containing Matrigel (1:1) were subcutaneously inoculated into the right upper abdominal region of each mouse for tumor development.
[0112] 6.5.1.3.3. Randomization The average tumor size was approximately 254.27 mm 3Randomization was initiated when the target number of mice was reached. A total of 48 mice were enrolled in the study and randomly assigned to six study groups of eight mice each. Randomization was performed using the "consistent distribution" method (Study Director™ software, version 3.1.399.19). The date of randomization is indicated as day 0.
[0113] 6.5.1.3.4. Observation and Data Collection After tumor inoculation, animals were checked daily for morbidity and mortality. During routine monitoring, animals were checked for any effects of tumor growth and treatment on behavior such as mobility, food and water consumption, weight gain / loss (weight was measured twice weekly after randomization), loss of eye / coat luster, and any other abnormalities. For each individual animal, the number of deaths and observed clinical signs were recorded in detail.
[0114] Tumor volume was measured twice a week after randomization using calipers at two dimensions, and the volume was expressed in mm using the formula: V=(L×W×W) / 2 3 As shown in the diagram, in the formula, V is the tumor volume, L is the tumor length (longest tumor dimension), and W is the tumor width (longest tumor dimension perpendicular to L). Medication and measurements of tumor and body weight were performed in a laminar flow cabinet. Body weight and tumor volume were measured using Study Director™ software (version 3.1.399.19).
[0115] 6.5.1.3.5. Administration of drug formulations and test substances The vehicle used for cilnidipine was 5% DMSO and corn oil. The vehicle used for gemcitabine was physiological saline. The dosage volume was adjusted according to body weight (dosage volume = 5 / 10 μL / g). Treatment was initiated on day 0 after randomization.
[0116] 6.5.1.3.6. Medication-free days and administration of supplement gels The study was planned as follows: (1) Mice showing a body weight loss (BWL) > 20% after one measurement would be euthanized; (2) Mice showing a BWL > 15% after one measurement would be given a drug-free day in isolation cage with daily monitoring for 72 hours, while other mice in the same group would receive medication as scheduled, with treatment for the isolated mouse resuming only if its BWL had recovered to < 10%; and (3) Mice showing a BWL > 10% would receive a supplement gel. BWL was calculated based on the BW on the first day of treatment.
[0117] 6.5.1.4. Research completed. 6.5.1.4.1. Research endpoints The study endpoint was defined as tumor growth inhibition rate (TGI). TGI% is an indicator of antitumor activity. TGI is expressed as: TGI(%) = 100 × (1 - T / C). T and C are the mean tumor volumes of the treatment group and control group on a specific day, respectively.
[0118] 6.5.1.4.2. Treatment complete. The treatment was performed for 21 days. After the treatment, a 2-week observation period was observed without medication.
[0119] 6.5.1.4.3. Humanitarian endpoints Humane endpoints were based on monitoring weight loss, tumor size, tumor appearance, and general animal welfare. The weight of all animals was monitored throughout the study, and animals were euthanized if they lost more than 20% of their body weight compared to their weight on the first day of treatment. Tumor volume was 3000 mm³. 3 If the number of mice exceeded a certain limit, they were to be euthanized. To prevent cannibalism, any animals exhibiting ulcerative or necrotic tumors were to be immediately isolated and kept in solitary housing with daily monitoring until euthanasia or until the tumor regression was complete. Mice with tumor ulcers covering approximately 25% or more of the tumor surface were to be euthanized.
[0120] 6.5.1.5. Statistical analysis To compare tumor volumes in different groups on pre-specified days, Bartlett's test was used to check the assumption of homogeneity of variance across all groups. If the p-value of Bartlett's test was >= 0.05, a one-way ANOVA was performed to test the overall equivalence of means across all groups. If the p-value of the one-way ANOVA was < 0.05, Dunnett's test was performed to compare each treatment group to the vehicle group. If the p-value of Bartlett's test was < 0.05, the Kruskal-Wallis test was performed to test the overall equivalence of medians across all groups. If the p-value of the Kruskal-Wallis test was < 0.05, a post-hoc test by performing Conover's nonparametric test was performed for all pairwise comparisons or to compare each treatment group to the vehicle group, both with one-step p-adjustment.
[0121] All statistical analyses were performed using the Ra language and environment for statistical computation and graphics (version 3.3.1). Unless otherwise specified, all tests were two-tailed tests, and p-values <0.05 were considered statistically significant.
[0122] 6.5.2. Results The results are shown in Figures 7A-7B and 8A-8B.
[0123] No signs of cachexia were observed in the vehicle group (Group 1). BWL > 15% was observed in mice in Groups 3, 4, 5, and 6. The mean body weight of each group at different time points is shown in Figure 7A. The body weight change curves for each group at different time points are shown in Figure 7B.
[0124] A trend toward antitumor activity was observed with cilnidipine as a monotherapy (group 4) and with cilnidipine in combination with gemcitabine (groups 5 and 6). In these cases, the calculated TGI at 20 days was 9.01%, 22.18%, and 33.06%, respectively (p>0.05). However, the observed antitumor activity did not reach statistical significance (Figures 8A-8B and Table 3 below).
[0125] [Table 3]
[0126] This study provides justification for the use of cilnidipine alone or in combination with gemcitabine in the treatment of cancers such as pancreatic cancer.
[0127] 7. Specific Embodiments This disclosure is illustrated below by specific embodiments. 1. A method for treating a subject having a disease or condition related to phagocytosis deficiency, which is optionally cancer, comprising administering a drug or combination of drugs containing a phagocytosis activator to the subject. 2. The method of Embodiment 1, wherein the drug or combination of drugs includes a mitochondrial fission inhibitor. 3. A method for treating a subject having a cancerous disease, comprising administering a drug or combination of drugs containing a mitochondrial fission inhibitor to the subject. 4. The method of Embodiment 2 or Embodiment 3, comprising administering a combination of drugs containing two or more mitochondrial fission inhibitors. 5. Any one of Embodiments 1 to 4, wherein the drug or combination of drugs comprises a Drp1 inhibitor. 6. Any one of Embodiments 1 to 5, wherein the drug or combination of drugs includes cilnidipine, P110, metformin, mdivi-1, berberine, pharmacoposly acceptable salts thereof or solvates thereof, or any combination thereof. 7. The drug or combination of drugs comprises cilnidipine or a pharmacoposly acceptable salt thereof or a solvate thereof, according to any one of Embodiments 1 to 6. 8. The drug or combination of drugs comprises a cilnidipine derivative or a pharmacoposly acceptable salt thereof or a solvate thereof, according to any one of Embodiments 1 to 7. 9. The drug or combination of drugs is given by formula (I):
[0128] [ka] The compound, or a pharmacoposly acceptable salt thereof, or a solvate thereof, (In the formula: R 1 is a phenyl compound substituted with 1 to 3 substituents, each substituent independently being NO2, NH2, OH, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl, wherein at least one substituent is NO2 or NH2; R 2 is H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl; R 3 is H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl; R 4 These are C1-C6 alkyl or C1-C6 haloalkyl; R 5 is phenyl or pyridinyl, where phenyl or pyridinyl is unsubstituted, or each substituent is independently substituted with 1 to 3 substituents which are NO2, NH2, OH, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl. (i) bond a exists and bonds b and c do not exist, or (ii) bonds b and c exist and bond a does not exist; A is NH if bond a is present, and N if bond b and bond c are present; m is an integer from 1 to 4; n is an integer from 1 to 3. Optionally, the compound of formula (I) is not cilnidipine. Any one of Embodiments 1 to 8. 10. The compound of formula (I) is formula (Ia):
[0129] [ka] The method of Embodiment 9, wherein the compound having the structure, or a pharmacoposly acceptable salt thereof, or a solvate thereof. 11. The compound of formula (I) is:
[0130] [ka] The method of Embodiment 9, wherein the compound having the structure, or a pharmacoposly acceptable salt thereof, or a solvate thereof. 12.R 1 teeth:
[0131] [ka] (In the formula, R 1a is NO2 or NH2, and R 1b and R 1c (Each of these is independently H, NO2, NH2, OH, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl.) The method is one of the embodiments 9 to 11. 13.R 1b and R 1c The method according to Embodiment 12, wherein each is independently H, NO2, NH2, OH, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 alkoxyalkyl. 14.R 1 teeth
[0132] [ka] The method of Embodiment 12. 15.R 1 teeth
[0133] [ka] The method of Embodiment 12. 16.R 1 teeth
[0134] [ka] The method of Embodiment 12. 17.R 1a The method is NO2, one of the embodiments 12 to 16. 18.R 1a The method is one of embodiments 12 to 16, wherein is NH2. 19.R 2 The method according to any one of embodiments 9 to 18, wherein is H, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 alkoxyalkyl. 20.R 2 The method of Embodiment 19, wherein is a C1-C3 alkyl group. 21.R 2 The method of embodiment 20, wherein CH3 is used. 22.R 3 The method according to any one of embodiments 9 to 21, wherein is H, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 alkoxyalkyl. 23.R 3 The method of Embodiment 22, wherein is a C1-C3 alkyl group. 24.R 3 The method of embodiment 23, wherein CH3 is used. 25.R 4 The method according to any one of embodiments 9 to 24, wherein is a C1-C3 alkyl or a C1-C3 haloalkyl. 26.R 4 The method of Embodiment 25, wherein is a C1-C3 alkyl group. 27.R 4 The method of embodiment 26, wherein CH3. 28.R 5 The method according to any one of embodiments 9 to 27, wherein is a phenyl molecule, which is either unsubstituted or has one to three substituents, each of which is independently NO2, NH2, OH, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl. 29.R 5The method of Embodiment 28, wherein is phenyl, and this phenyl is either unsubstituted or each of the substituents is independently substituted with 1 to 3 substituents which are NO2, NH2, OH, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 alkoxyalkyl. 30.R 5 The method of Embodiment 28, wherein is an unsubstituted phenyl. 31.R 5 The method according to any one of Embodiments 9 to 27, wherein is a pyridinyl molecule, which is either unsubstituted or each of the substituents is independently substituted with 1 to 3 substituents which are NO2, NH2, OH, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl. 32.R 5 The method of Embodiment 31, wherein is a pyridinyl molecule, and this pyridinyl molecule is either unsubstituted or each of the substituents is independently substituted with 1 to 3 substituents which are NO2, NH2, OH, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 alkoxyalkyl. 33.R 5 The method of Embodiment 31, wherein is an unsubstituted pyridinyl. 34.R 5 The pyridinyl is 4-pyridyl, in any one of embodiments 31 to 33. 35.R 5 The pyridinyl is 3-pyridyl, in any one of embodiments 31 to 33. 36.R 5 The pyridinyl is 2-pyridyl, in any one of embodiments 31 to 33. 37.m is 2, one of the methods of Embodiments 9 to 36. 38.n is 1, any one of embodiments 9 to 36. 39.R 1 teeth:
[0135] [ka] (In the formula, R 1a It is NO2 or NH2; R 2 , R 3 , and R 4 It is CH3; R 5 is an unsubstituted phenyl or unsubstituted pyridinyl; m is 2; and n is 1) The method of Embodiment 10. 40.R 5 The method of Embodiment 39, wherein is an unsubstituted 4-pyridyl. 41. The method of Embodiment 9, wherein the compound of formula (I) is cilnidipine or a pharmacoposly acceptable salt thereof or a solvate thereof. 42. The compound of formula (I) is
[0136] [ka] The method of Embodiment 9, or the pharmacologically acceptable salt thereof or a solvate thereof. 43. The compound of formula (I) is
[0137] [ka] The method of Embodiment 9, or the pharmacologically acceptable salt thereof or a solvate thereof. 44. The compound of formula (I) is
[0138] [ka] The method of Embodiment 9, or the pharmacologically acceptable salt thereof or a solvate thereof. 45. The compound of formula (I) is
[0139] [ka] The method of Embodiment 9, or the pharmacologically acceptable salt thereof or a solvate thereof. 46. The compound of formula (I) is
[0140] [ka] The method of Embodiment 9, or the pharmacologically acceptable salt thereof or a solvate thereof. 47. The compound of formula (I) is
[0141] [ka] The method of Embodiment 9, or the pharmacologically acceptable salt thereof or a solvate thereof. 48. The compound of formula (I) is
[0142] [ka] The method of Embodiment 9, or the pharmacologically acceptable salt thereof or a solvate thereof. 49. The compound of formula (I) is
[0143] [ka] The method of Embodiment 9, or the pharmacologically acceptable salt thereof or a solvate thereof. 50. The compound of formula (I) is
[0144] [ka] The method of Embodiment 9, or the pharmacologically acceptable salt thereof or a solvate thereof. 51. The drug or combination of drugs comprises metformin or a pharmacologically acceptable salt thereof or a solvate thereof, according to any one of Embodiments 1 to 50. 52. The drug or combination of drugs comprises P110 or a pharmacoposly acceptable salt thereof or a solvate thereof, according to any one of Embodiments 1 to 51. 53. The drug or combination of drugs comprises mdivi-1 or a pharmacologically acceptable salt thereof, or a solvate thereof, according to any one of Embodiments 1 to 52. 54. The drug or combination of drugs comprises berberine or a pharmacoposly acceptable salt thereof or a solvate thereof, according to any one of Embodiments 1 to 53. 55. Any one of Embodiments 1 to 54, wherein the drug or combination of drugs includes a drug or combination of drugs that activates Toll-like receptors (TLRs), Dectin-1, mannose receptors, scavenger receptor A, CD14, CD36, opsonin receptors, apoptotic body receptors, or combinations thereof. 56. The method of Embodiment 55, wherein the drug or combination of drugs includes a drug that activates a TLR. 57. The method of Embodiment 56, comprising the step of administering a combination of drugs containing two or more drugs that activate TLRs. 58. The drug or combination of drugs comprises a drug that activates Dectin-1, in any one of the embodiments 55 to 57. 59. The method of Embodiment 58, comprising the step of administering a combination of drugs containing two or more drugs that activate Dectin-1. 60. The drug or combination of drugs comprises a drug that activates a mannose receptor, one of the methods of Embodiments 55 to 59. 61. The method of Embodiment 60, comprising the step of administering a combination of drugs comprising two or more drugs that activate mannose receptors. 62. Any one of embodiments 55 to 61, wherein the drug or combination of drugs comprises a drug that activates scavenger receptor A. 63. The method of Embodiment 62, comprising the step of administering a combination of drugs comprising two or more drugs that activate scavenger receptor A. 64. The drug or combination of drugs includes a drug that activates CD14, in any one of the embodiments 55 to 63. 65. The method of Embodiment 64, comprising administering a combination of drugs containing two or more drugs that activate CD14. 66. The agent or combination of agents comprises an agent that activates CD36, in any one of the embodiments 55 to 65. 67. The method of Embodiment 66, comprising administering a combination of drugs containing two or more drugs that activate CD36. 68. Any one of embodiments 55 to 67, wherein the drug or combination of drugs includes a drug that activates opsonin receptors. 69. The method of Embodiment 68, comprising administering a combination of drugs including two or more drugs that activate opsonin receptors. 70. The method of Embodiment 55, wherein the drug or combination of drugs includes a drug that activates apoptotic body receptors. 71. The method of Embodiment 70, comprising administering a combination of drugs including two or more drugs that activate apoptotic body receptors. 72. Any one of Embodiments 55 to 71, wherein the drug or combination of drugs comprises 1,3-beta-glucan, mannan, lipopolysaccharide, lipoteichoic acid, lipopolysaccharide-binding protein, Plasmodium falciparum-infected red blood cells, IgG, IgA, IgE, or phosphatidylserine. 73. Any one of Embodiments 1 to 72, wherein the drug or combination of drugs includes a drug that activates PGC1α. 74. The method of Embodiment 73, comprising administering a combination of drugs containing two or more drugs that activate PGC1α. 75. The method of Embodiment 73 or Embodiment 74, wherein the drug or combination of drugs comprises metformin or a pharmacologically acceptable salt thereof or a solvate thereof. 76. The drug or combination of drugs is any one of Embodiments 1 to 75, comprising a drug that inhibits the PI3K-AKT-mTOR pathway. 77. The method of Embodiment 76, wherein the drug or combination of drugs comprises a PI3K inhibitor. 78. The method of Embodiment 77, comprising administering a combination of drugs containing 2 or more PIK3 inhibitors. 79. Any one of embodiments 76 to 78, wherein the drug or combination of drugs comprises an AKT inhibitor. The method of Embodiment 79, comprising administering a combination of drugs containing 80.2 or more AKT inhibitors. 81. Any one of embodiments 76 to 80, wherein the drug or combination of drugs comprises an mTOR inhibitor. 82. The method of Embodiment 81, comprising administering a combination of drugs containing 2 or more mTOR inhibitors. 83. The drug or combination of drugs comprises rapamycin or a pharmacoposly acceptable salt thereof or a solvate thereof, according to any one of Embodiments 76 to 82. 84. The drug or combination of drugs comprises one or more lactate-releasing bacterial species, as described in any one of Embodiments 1 to 83. 85. The method of Embodiment 84, wherein the drug or combination of drugs comprises a bacterium of the genus Bifidobacterium and / or Lactobacillus acidophilus. 86. Any one of Embodiments 1 to 85, wherein the drug or combination of drugs comprises a component or combination of components of a cell-free extract derived from a culture medium of lactate-releasing bacteria. 87. The method of Embodiment 86, wherein the lactic acid-releasing bacteria include bacteria of the genus Bifidobacterium and / or Lactobacillus acidophilus. 88. One of the methods of Embodiments 1 to 87, wherein one or more drugs in a drug or combination of drugs are formulated together with a bile acid derivative. 89. The method of Embodiment 88, wherein the bile acid derivative is ursodeoxycholic acid or a pharmacoacidically acceptable salt thereof or a solvate thereof. 90. The disease is a cancer having a KRAS mutation, according to any one of Embodiments 1 to 89. 91. The method of embodiment 90, wherein the cancer is a blood cancer. 92. The method of embodiment 90, in which cancer is a solid tumor. 93. Cancer is leukemia, method of embodiment 90. 94. The method of embodiment 90, in which the cancer is lymphoma. 95. The method of embodiment 90, in which the cancer is myeloma. 96. The method of embodiment 90, wherein the cancer is multiple myeloma. 97. The method of embodiment 90, wherein the cancer is acute myeloid leukemia. 98. The method of embodiment 90, wherein the cancer is acute lymphoblastic leukemia. 99. The method of Embodiment 90, wherein the cancer is non-Hodgkin lymphoma. 100. The method of Embodiment 90, wherein the cancer is diffuse large B-cell lymphoma. 101. The method of Embodiment 90, wherein the cancer is melanoma, and optionally the melanoma has a BRAF mutation. 102. The cancer is leiomyosarcoma, according to the method of embodiment 90. 103. The cancer is breast cancer, according to the method of Embodiment 90. 104. The method of Embodiment 90, wherein the cancer is liver cancer. 105. The method of Embodiment 90, wherein the cancer is colorectal cancer. 106. The method of Embodiment 90, wherein the cancer is pancreatic cancer, and optionally, the pancreatic cancer is pancreatic ductal adenocarcinoma. 107. The method of Embodiment 90, wherein the cancer is lung cancer, and the lung cancer is optionally small cell lung cancer or non-small cell lung cancer, optionally lung adenocarcinoma. 108. The cancer is osteosarcoma, according to the method of Embodiment 90. 109. The method of Embodiment 90, wherein the cancer is head and neck cancer. 110. Any one of Embodiments 90 to 109, which, when directly or indirectly dependent on Embodiment 3, includes administering a mitochondrial fission inhibitor as monotherapy for cancer. 111. Any one of embodiments 90 to 109, wherein one or more additional drugs are administered to the subject. 112.1 The method of Embodiment 111, wherein one or more additional agents include CD47 inhibitors and / or SIRPα inhibitors. 113.1 The method of Embodiment 112, wherein one or more additional agents include CD47 inhibitors. 114. The method of Embodiment 113, wherein the CD47 inhibitor comprises an antibody or an antigen-binding fragment thereof. 115. The method of Embodiment 113, wherein the CD47 inhibitor comprises a SIRPα-Fc fusion protein. 116. The method of Embodiment 113, wherein the CD47 inhibitor comprises a SIRPα variant protein. 117. The method of Embodiment 113, in which the CD47 inhibitor is maglorimab. 118. The method of Embodiment 113, wherein the CD47 inhibitor is CC-90002. 119. The method of Embodiment 113, wherein the CD47 inhibitor is AO-176. 120. The method of Embodiment 113, wherein the CD47 inhibitor is IBI-188. 121. The method of Embodiment 113, wherein the CD47 inhibitor is SHR-1063. 122. The method of Embodiment 113, wherein the CD47 inhibitor is AMMS4-G4. 123. The method of Embodiment 113, in which the CD47 inhibitor is a SIRPα-Fc fusion protein. 124. The method of Embodiment 113, wherein the CD47 inhibitor is TTI-621. 125. The method of Embodiment 113, wherein the CD47 inhibitor is ALX148. 126. The method of Embodiment 113, wherein the CD47 inhibitor is CV1. 127.1 One of the methods of Embodiments 112 to 126, wherein one or more additional agents include a SIRPα inhibitor. 128. The method of Embodiment 127, wherein the SIRPα inhibitor comprises an antibody or an antigen-binding fragment thereof. 129. The method of Embodiment 127, wherein the SIRPα inhibitor is KWAR23. 130. The method of Embodiment 127, wherein the SIRPα inhibitor is CC-95251. 131. The method of Embodiment 127, wherein the SIRPα inhibitor is BI 765063. 132. The method of Embodiment 127, wherein the SIRPα inhibitor comprises soluble CD47 peptide. 133.1 or more additional drugs, including standard treatment for cancer, one of the methods of Embodiments 111 to 132. 134. If the cancer is pancreatic cancer, one or more additional agents comprising gemcitabine and / or paclitaxel, according to any one of embodiments 111 to 133. 135. If the cancer is lung adenocarcinoma, one or more additional agents include cisplatin and / or carboplatin, according to any one of the embodiments 111 to 133. 136. If the cancer is colorectal cancer, one or more additional agents include cetuximab and / or panitumumab, according to any one of embodiments 111 to 133. 137.1 or more additional agents, comprising an anti-PD1 antibody and / or an anti-PD-L1 antibody, according to any one of Embodiments 111 to 136. 138.1 The method of Embodiment 137, wherein one or more additional agents include an anti-PD1 antibody. 139. The method of Embodiment 138, wherein the anti-PD1 antibody is cemiprimab. 140. The method of Embodiment 138, wherein the anti-PD1 antibody is nivolumab. 141. The method of Embodiment 138, wherein the anti-PD1 antibody is pembrolizumab. 142.1 or more additional agents, including an anti-PD-L1 antibody, according to any one of Embodiments 137 to 141. 143. The method of Embodiment 142, wherein the anti-PD-L1 antibody is avelumab. 144. The method of Embodiment 142, wherein the anti-PD-L1 antibody is durvalumab. 145. The method of Embodiment 142, wherein the anti-PD-L1 antibody is atezolizumab. 146. Any one of embodiments 111 to 145, further comprising administering to one or more additional drugs. 147. One or more additional drugs are formulated together with a bile acid derivative, according to any one of embodiments 111 to 146. 148. The method of Embodiment 147, wherein the bile acid derivative is ursodeoxycholic acid or a pharmacoagulably acceptable salt thereof or a solvate thereof. 149. Any one of Embodiments 1 to 89, in which the disease or condition related to phagocytosis deficiency is directly or indirectly dependent on Embodiment 1, is an infection, neurodegenerative disease, inflammation, inflammatory disease, or lysosomal disease. 150. The method of Embodiment 149, wherein the disease or condition is an infectious disease. 151. An infectious disease is caused by bacteria, according to the method of Embodiment 150. 152. An infectious disease caused by a virus, according to the method of Embodiment 150. 153. The method of Embodiment 149, wherein the disease or condition is a neurodegenerative disease. 154. The method of Embodiment 153, wherein the neurodegenerative disease is Alzheimer's disease (AD) or other dementia, Parkinson's disease (PD), Nasu-Hakola disease, prion disease, amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, Huntington's disease, Lewy body dementia, spinal muscular atrophy, progressive supranuclear palsy (PSP), or adrenoleukodystrophy (ALD). 155. The neurodegenerative disease is Alzheimer's disease (AD), according to the method of Embodiment 154. 156. Neurodegenerative disease is dementia, according to the method of Embodiment 154. 157. The neurodegenerative disease is Parkinson's disease (PD), according to the method of Embodiment 154. 158. The neurodegenerative disease is Nasu-Hakola disease, according to the method of Embodiment 154. 159. A neurodegenerative disease is a prion disease, according to the method of Embodiment 154. 160. The neurodegenerative disease is amyotrophic lateral sclerosis (ALS), according to the method of Embodiment 154. 161. The neurodegenerative disease is Friedreich's ataxia, according to the method of Embodiment 154. 162. The neurodegenerative disease is Huntington's disease, according to the method of Embodiment 154. 163. The neurodegenerative disease is Lewy body disease, according to the method of Embodiment 154. 164. The neurodegenerative disease is spinal muscular atrophy, according to the method of Embodiment 154. 165. The neurodegenerative disease is progressive supranuclear palsy (PSP), according to the method of Embodiment 154. 166. The neurodegenerative disease is adrenoleukodystrophy (ALD), according to the method of Embodiment 154. 167. The method of Embodiment 149, wherein the disease or condition is inflammation. 168. The method of Embodiment 149, wherein the disease is an inflammatory disease. 169. Inflammatory disease is an autoimmune disease, method of embodiment 168. 170. The method of Embodiment 169, wherein the autoimmune disease is systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), or autoimmune lymphoproliferative syndrome (ALPS). 171. The autoimmune disease is SLE, according to the method of embodiment 170. 172. The method of embodiment 170 in which the autoimmune disease is RA. 173. The autoimmune disease is ALPS, according to the method of Embodiment 170. 174. The method of Embodiment 149, wherein the disease is a lysosomal storage disorder. 175. The method of Embodiment 174, wherein the lysosomal storage disorder is Gaucher disease, Fabry disease, Niemann-Pick disease, Hunter syndrome, glycogen storage disease type II (Pompe disease), or Tay-Sachs disease. 176. Gaucher disease is a lysosomal storage disorder, according to the method of Embodiment 175. 177. Lysosomal storage disorder is Fabry disease, according to the method of Embodiment 175. 178. Lysosomal storage disorder is Niemann-Pick disease, according to the method of Embodiment 175. 179. Lysosomal storage disorder is Hunter syndrome, according to the method of Embodiment 175. 180. Lysosomal storage disorder is glycogen storage disease type II (Pompe disease), according to the method of Embodiment 175. 181. Lysosomal storage disorder is Tay-Sachs disease, according to the method of Embodiment 175. 182. The method of any one of Embodiments 1 to 89, wherein when directly or indirectly dependent on Embodiment 1, the disease or condition associated with defective phagocytosis is a musculoskeletal degenerative disease. 183. The method of Embodiment 182, wherein the musculoskeletal degenerative disease is muscular dystrophy. 184. The method of Embodiment 183, wherein the muscular dystrophy is Duchenne muscular dystrophy (DMD). 185. The method of any one of Embodiments 1 to 184, wherein the subject has defective phagocytosis. 186. A method of treating a subject having Duchenne muscular dystrophy (DMD), comprising administering to the subject a therapeutically effective amount of cilnidipine, or a pharmacologically acceptable salt thereof, or a solvate thereof. 187. A combination comprising one or more phagocytosis activators and a CD47 inhibitor and / or a SIRPα inhibitor, optionally wherein the one or more phagocytosis activators comprise the one or more phagocytosis activators described in Embodiments 1 to 89, and optionally wherein the CD47 inhibitor and / or the SIRPα inhibitor is any CD47 inhibitor or SIRPα inhibitor described in any of Embodiments 112 to 132. 188. The combination of Embodiment 187 for use in the treatment of a disease or condition associated with defective phagocytosis. 189. The combination for use according to Embodiment 188, wherein the disease or condition associated with defective phagocytosis is cancer, and optionally the cancer is the cancer described in any one of Embodiments 90 to 109. 190. A mitochondrial fission inhibitor or combination of mitochondrial fission inhibitors for use in treating cancer, optionally wherein the mitochondrial fission inhibitor or combination of mitochondrial fission inhibitors comprises the mitochondrial fission inhibitor or combination of mitochondrial fission inhibitors described in any one of Embodiments 3 to 54, and optionally wherein the cancer is the cancer described in any one of Embodiments 90 to 109. 191. A mitochondrial fission inhibitor or combination of mitochondrial fission inhibitors for use according to Embodiment 190, for use as a monotherapy. 192. A mitochondrial fission inhibitor or combination of mitochondrial fission inhibitors for use according to Embodiment 191, for use in combination with one or more further agents. 193. The mitochondrial fission inhibitor or combination of mitochondrial fission inhibitors for use according to Embodiment 192, wherein the one or more further agents comprise one or more agents according to any of Embodiments 55 to 89 and 111 to 148. 194. A mitochondrial fission inhibitor or combination of mitochondrial fission inhibitors for use in the treatment of a disease or condition associated with defective phagocytosis, optionally, the mitochondrial fission inhibitor or combination of mitochondrial fission inhibitors comprises the mitochondrial fission inhibitor or combination of mitochondrial fission inhibitors according to any one of Embodiments 3 to 54. 195. A mitochondrial fission inhibitor or combination of mitochondrial fission inhibitors for use according to Embodiment 194, for use in combination with one or more further agents. 196. The mitochondrial fission inhibitor or combination of mitochondrial fission inhibitors for use according to Embodiment 195, wherein the one or more further agents comprise one or more agents according to any of Embodiments 55 to 89. 197. The mitochondrial fission inhibitor for use according to any one of Embodiments 194 to 196, wherein the disease or condition associated with defective phagocytosis is the disease or condition according to any one of Embodiments 149 to 184. 198. An agent or combination of agents for use in a method of treating a subject having a disease or condition associated with defective phagocytosis, wherein the agent or combination of agents comprises a phagocytosis activator, optionally: (a) the disease or condition associated with defective phagocytosis is cancer, optionally, the cancer is pancreatic cancer; and / or (b) The drug or combination of drugs includes cilnidipine or a pharmacoposly acceptable salt thereof or a solvate thereof. A drug or combination of drugs for use. 199. A drug or combination of drugs for use according to Embodiment 198, comprising a mitochondrial fission inhibitor. 200. A drug or drug combination comprising a Drp1 inhibitor for use according to Embodiment 198 or Embodiment 199. 201. A drug or drug combination for use according to any one of Embodiments 198-200, comprising cilnidipine, P110, metformin, mdivi-1, berberine, pharmacokinetically acceptable salts thereof or solvates thereof, or any combination thereof. 202. A drug or drug combination for use according to any one of Embodiments 198 to 201, comprising cilnidipine or a pharmacoposly acceptable salt thereof or a solvate thereof. 203. The drug or combination of drugs is given by formula (I):
[0145] [ka] The compound, or a pharmacoposly acceptable salt thereof, or a solvate thereof, (In the formula: R 1 is a phenyl compound substituted with 1 to 3 substituents, each substituent independently being NO2, NH2, OH, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl, wherein at least one substituent is NO2 or NH2; R 2 is H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl; R 3 is H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl; R 4 These are C1-C6 alkyl or C1-C6 haloalkyl; R 5 is phenyl or pyridinyl, where phenyl or pyridinyl is unsubstituted, or each substituent is independently substituted with 1 to 3 substituents which are NO2, NH2, OH, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl. (i) bond a exists and bonds b and c do not exist, or (ii) bonds b and c exist and bond a does not exist; A is NH if bond a is present, and N if bond b and bond c are present; m is an integer from 1 to 4; n is an integer from 1 to 3. Optionally, the compound of formula (I) is not cilnidipine. A drug or combination of drugs for use according to any one of embodiments 198 to 201. 204. A drug or drug combination for use according to any one of Embodiments 198 to 203, comprising a drug or drug combination that activates Toll-like receptors (TLRs), Dectin-1, mannose receptors, scavenger receptor A, CD14, CD36, opsonin receptors, apoptotic body receptors, or combinations thereof. 205. A drug or drug combination for use according to Embodiment 204, comprising 1,3-beta-glucan, mannan, lipopolysaccharide, lipoteichoic acid, lipopolysaccharide-binding protein, Plasmodium falciparum-infected red blood cells, IgG, IgA, IgE, or phosphatidylserine. 206. A drug or combination of drugs for use according to any one of embodiments 198 to 205, comprising a drug that activates PGC1α. 207. A drug or drug combination for use according to Embodiment 206, comprising metformin or a pharmacoposly acceptable salt thereof or a solvate thereof. 208. A drug or combination of drugs for use according to any one of Embodiments 198 to 207, comprising a drug that inhibits the PI3K-AKT-mTOR pathway. 209. A drug or combination of drugs for use in accordance with Embodiment 208, comprising (i) a PI3K inhibitor, (ii) an AKT inhibitor, (iii) an mTOR inhibitor, (iv) rapamycin or a pharmacoacceptable salt thereof or a solvate thereof, or (v) any combination of the foregoing. 210. A drug or drug combination comprising one or more lactic acid-releasing bacterial species, optionally comprising a bacterium of the genus Bifidobacterium and / or Lactobacillus acidophilus, for use according to any one of Embodiments 198 to 209. 211. A drug or drug combination comprising a cell-free extract component or component combination derived from a culture medium of lactate-releasing bacteria, optionally comprising a bacterium of the genus Bifidobacterium and / or Lactobacillus acidophilus, for use according to any one of Embodiments 198 to 210. 212. A drug or drug combination for use according to any one of Embodiments 198 to 211, wherein one or more drugs in a drug or drug combination are formulated together with a bile acid derivative, and optionally the bile acid derivative is ursodeoxycholic acid or a pharmacoagulably acceptable salt thereof or a solvate thereof. 213. Diseases or conditions associated with phagocytosis insufficiency are, optionally, cancers with KRAS mutations, and optionally, cancers: (a) Pancreatic cancer; (b) hematologic cancer; (c) solid tumor; (d) leukemia; (e) lymphoma; (f) myeloma; (g) multiple myeloma; (h) acute myeloid leukemia; (i) acute lymphoblastic leukemia; (j) non-Hodgkin lymphoma; (k) diffuse large B-cell lymphoma; (l) melanoma, optionally having a BRAF mutation; (m) leiomyosarcoma; (n) breast cancer; (o) liver cancer; (p) colorectal cancer; (q) lung cancer, optionally small cell lung cancer or non-small cell lung cancer, optionally lung adenocarcinoma; (r) osteosarcoma; or (s) head and neck cancer which is, the medicament or combination of medicaments for use according to any one of embodiments 198 to 212. 214. The medicament or combination of medicaments for use according to embodiment 213, wherein the cancer is pancreatic cancer, and optionally, the pancreatic cancer is pancreatic ductal adenocarcinoma. 215. The medicament for use according to embodiment 213 or embodiment 214, wherein the medicament is a mitochondrial fission inhibitor, and the method comprises the step of administering the mitochondrial fission inhibitor as a monotherapy for cancer. 216. The medicament or combination of medicaments for use according to embodiment 213 or embodiment 214, wherein the method comprises the step of administering one or more further medicaments to the subject. 217. The medicament or combination of medicaments for use according to embodiment 216, wherein the one or more further medicaments comprise a CD47 inhibitor and / or a SIRPα inhibitor. 218. The one or more further medicaments comprise a CD47 inhibitor, and optionally, the CD47 inhibitor is: (a) an antibody or an antigen-binding fragment thereof; (b) SIRPα-Fc fusion protein; (c) SIRPα variant protein; (d) Maglorimab; (e) CC-90002; (f)AO-176; (g) IBI-188; (h)SHR-1063; (i) AMMS4-G4; (j)TTI-621; (k)ALX148; or (l)CV1, That is, A drug or combination of drugs for use according to Embodiment 217. 219.1 or more additional drugs include SIRPα inhibitors, and optionally, SIRPα inhibitors are: (a) an antibody or an antigen-binding fragment thereof; (b) KWAR23; (c)CC-95251; (d) BI 765063; or (e) Soluble CD47 peptide That is, A drug or combination of drugs for use according to Embodiment 217 or Embodiment 218. 220.1 or more additional drugs, including standard treatments for cancer, drugs or combinations of drugs for use in accordance with any one of embodiments 216 to 219. 221. If the cancer is pancreatic cancer, one or more additional agents or combinations of agents for use according to any one of embodiments 216-220, comprising gemcitabine and / or paclitaxel. 222. If the cancer is pancreatic cancer, one or more additional agents or combinations of agents for use according to Embodiment 221, comprising gemcitabine. 223. If the cancer is lung adenocarcinoma, one or more additional agents or combinations of agents for use according to any one of embodiments 216-220, comprising cisplatin and / or carboplatin. 224. If the cancer is colorectal cancer, one or more additional agents or combination of agents for use according to any one of embodiments 216-220, comprising cetuximab and / or panitumumab. 225.1 or more additional agents, optionally including an anti-PD1 antibody which is cemiprimab, nivolumab, or pembrolizumab, and / or optionally an anti-PD-L1 antibody which is avelumab, durvalumab, or atezolizumab, for use in accordance with any one of Embodiments 216 to 224. 226. A drug or combination of drugs for use according to any one of embodiments 216 to 225, further comprising the step of administering one or more additional drugs. 227. One or more further agents are formulated together with a bile acid derivative, and optionally the bile acid derivative is ursodeoxycholic acid or a pharmacoposly acceptable salt thereof or a solvate thereof, for use according to any one of Embodiments 216 to 226. 228. Diseases or conditions associated with phagocytosis insufficiency include: (a) Musculoskeletal degenerative diseases, such as Duchenne muscular dystrophy (DMD), which may be any other muscular dystrophy; (b) any infection caused by bacteria or viruses; (c) Any neurodegenerative disease that is Alzheimer's disease (AD) or other dementia, Parkinson's disease (PD), Nasu-Hakola disease, prion disease, amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, Huntington's disease, Lewy body dementia, spinal muscular atrophy, progressive supranuclear palsy (PSP), or adrenoleukodystrophy (ALD); (d) inflammation; (e) optionally, an inflammatory disease that is an autoimmune disease such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), or autoimmune lymphoproliferative syndrome (ALPS); or (f) Any lysosomal storage disorder, such as Gaucher disease, Fabry disease, Niemann-Pick disease, Hunter syndrome, glycogen storage disease type II (Pompe disease), or Tay-Sachs disease. That is, A drug or combination of drugs for use according to any one of embodiments 198 to 212. 229. A disease or condition associated with phagocytosis insufficiency is Duchenne muscular dystrophy (DMD), a drug or combination of drugs for use according to Embodiment 228. 230. A drug or combination of drugs for use according to any one of embodiments 198 to 229, for subjects having phagocytic dysfunction. 231. A drug for use in a method of treating a subject having pancreatic cancer, wherein the pancreatic cancer is pancreatic ductal adenocarcinoma. 232. A drug intended for use as monotherapy, in accordance with Embodiment 231. 233. A method for use of a drug according to Embodiment 232, comprising the step of administering to a subject an amount of the drug effective in slowing tumor growth in the subject. 234. A drug for use according to Embodiment 231, which is used in combination with gemcitabine. 235. A drug for use according to Embodiment 234, comprising the step of administering to a subject an amount of a drug and an amount of gemcitabine that together are effective in slowing tumor growth in the subject. 236. A drug for use in methods of treating subjects having Duchenne muscular dystrophy (DMD), which is cilnidipine or a pharmacoacceptable salt thereof or a solvate thereof. 237. A method for use according to Embodiment 236, comprising the step of administering an amount of drug effect that reduces creatinine kinase (CK) and / or lactose dehydrogenase (LDH) in the plasma of a subject. 238. A pharmaceutical composition containing a phagocyte having enhanced phagocytic activity. 239. A pharmaceutical composition of Embodiment 238, comprising a phagocyte contacted ex vivo with one or more mitochondrial fission inhibitors. 240.1 or more mitochondrial fission inhibitors, comprising the pharmaceutical composition of Embodiment 239, which includes a mitochondrial fission inhibitor or a combination of mitochondrial fission inhibitors described in any one of Embodiments 3 to 54. 241. A pharmaceutical composition of Embodiment 239 or Embodiment 240 comprising cilnidipine or a pharmacoacceptable salt thereof or a solvate thereof, wherein one or more mitochondrial fission inhibitors. 242. A pharmaceutical composition according to any one of Embodiments 238 to 241, comprising phagocytes, monocytes, macrophages, neutrophils, dendritic cells, mast cells, or any combination thereof. 243. The pharmaceutical composition of Embodiment 242, wherein the phagocytes contain monocytes. 244. A pharmaceutical composition of Embodiment 242 or Embodiment 243, wherein the phagocytosis comprises a macrophage. 245. A pharmaceutical composition according to any one of embodiments 242 to 244, wherein the phagocytide contains neutrophils. 246. A pharmaceutical composition according to any one of embodiments 242 to 245, wherein the phagocytes contain dendritic cells. 247. A pharmaceutical composition according to any one of embodiments 242 to 246, wherein the phagocytides contain mast cells. 248. Any one of the 238-247 embodiments of a pharmaceutical composition for use in a method of treating a subject having a disease or condition related to phagocytosis deficiency. 249. A pharmaceutical composition for use according to Embodiment 248, wherein the disease or condition related to phagocytosis insufficiency is the disease or condition described in any one of Embodiments 90-109 and 149-185. 250. A pharmaceutical composition for use according to Embodiment 249, wherein the disease or condition is cancer. 251. A pharmaceutical composition for use according to any one of embodiments 248 to 250, wherein the phagocyte is autologous to the subject. 252. A pharmaceutical composition for use according to any one of embodiments 248 to 250, wherein phagocyte is homogeneous with respect to the subject. 253. A method for preparing any one of the pharmaceutical compositions of Embodiments 239 to 252, comprising the step of ex vivo contacting one or more mitochondrial fission inhibitors with phagocytes. 254. Optionally, a mitochondrial fission inhibitor for use in the preparation of any one of the pharmaceutical compositions of Embodiments 239 to 252, comprising a mitochondrial fission inhibitor described in any one of Embodiments 3 to 54. 255. A mitochondrial fission inhibitor for use according to Embodiment 254, which is cilnidipine or a pharmacoacceptable salt thereof or a solvate thereof.
[0146] 8. Citation of References All publications, patents, patent applications, and other documents cited herein are incorporated herein by reference to the same extent in whole for all purposes, as if each individual publication, patent, patent application, or other document were individually intended to be incorporated by reference for any purpose. In the event of any inconsistency between one or more teachings of the references incorporated herein and the teachings of this disclosure, the teachings of this disclosure shall prevail.
Claims
1. A drug or combination of drugs for use in a method of treating a subject having a musculoskeletal degenerative disease, comprising: The agent or combination of agents comprises a phagocytosis activator. A drug or drug combination.
2. A drug or drug combination for use as described in claim 1, wherein the drug or drug combination comprises cilnidipine or a pharmacologically acceptable salt thereof or a solvate thereof.
3. The drug or drug combination comprises: (a) a mitochondrial fission inhibitor, (b) a Drp1 inhibitor, or (c) cilnidipine, P110, metformin, mdivi-1, berberine, pharmacologically acceptable salts thereof, or solvates thereof, or any combination of the foregoing.
2. The drug or drug combination for use according to claim 1, comprising:
4. The drug or drug combination has the formula (I): 【Chemistry 1】 or a pharmacologically acceptable salt or solvate thereof. (In the formula: R 1 is phenyl substituted with 1 to 3 substituents, each of which is independently NO 2 , N.H. 2 , O.H., C. 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, or C 1 ~C 6 Alkoxyalkyl, provided that at least one of the substituents is NO. 2 or NH 2 and R 2 is H, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, or C 1 ~C 6 is alkoxyalkyl; R 3 is H, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, or C 1 ~C 6 is alkoxyalkyl; R 4 is C 1 ~C 6 Alkyl or C 1 ~C 6 haloalkyl; R 5 is phenyl or pyridinyl, wherein said phenyl or pyridinyl is unsubstituted or each of the substituents is independently NO 2 , N.H. 2 , O.H., C. 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, or C 1 ~C 6 substituted with 1 to 3 substituents which are alkoxyalkyl; (i) bond a is present and bond b and bond c are absent, or (ii) bond b and bond c are present and bond a is absent; A is NH when bond a is present, and N when bond b and bond c are present; m is an integer from 1 to 4; n is an integer from 1 to 3; Optionally, the compound of formula (I) is not cilnidipine. A drug or drug combination for use according to any one of claims 1 to 3.
5. The drug or drug combination for use according to any one of claims 1 to 4, wherein the drug or drug combination comprises a drug or drug combination that activates a toll-like receptor (TLR), dectin-1, mannose receptor, scavenger receptor A, CD14, CD36, an opsonic receptor, an apoptotic body receptor, or a combination thereof.
6. 6. The drug or drug combination for use according to claim 5, wherein the drug or drug combination comprises 1,3-beta glucan, mannan, lipopolysaccharide, lipoteichoic acid, lipopolysaccharide binding protein, Plasmodium falciparum infected red blood cells, IgG, IgA, IgE or phosphatidylserine.
7. The drug or drug combination for use according to any one of claims 1 to 6, wherein said drug or drug combination comprises a drug that activates PGC1α.
8. 8. The drug or drug combination for use according to claim 7, wherein said drug or drug combination comprises metformin or a pharmacologically acceptable salt or solvate thereof.
9. The agent or combination of agents for use according to any one of claims 1 to 8, wherein said agent or combination of agents comprises an agent that inhibits the PI3K-AKT-mTOR pathway.
10. The drug or drug combination for use according to claim 9, wherein the drug or drug combination comprises (i) a PI3K inhibitor, (ii) an AKT inhibitor, (iii) an mTOR inhibitor, (iv) rapamycin or a pharmacologically acceptable salt or solvate thereof, or (v) a combination of the foregoing.
11. 11. The drug or drug combination for use according to any one of claims 1 to 10, wherein the drug or drug combination comprises one or more lactic acid releasing bacterial species, optionally the drug or drug combination comprises a bacterium of the genus Bifidobacterium and / or Lactobacillus acidophilus.
12. 12. The drug or drug combination for use according to any one of claims 1 to 11, wherein the drug or drug combination comprises a component or a combination of components of a cell-free extract from a lactate releasing bacteria culture medium, optionally wherein the lactate releasing bacteria comprises a bacterium of the genus Bifidobacterium and / or Lactobacillus acidophilus.
13. 13. The drug or drug combination for use according to any one of claims 1 to 12, wherein one or more drugs in the drug or drug combination are formulated with a bile acid derivative, and optionally the bile acid derivative is ursodeoxycholic acid or a pharmacologically acceptable salt or solvate thereof.
14. The drug or drug combination for use according to any one of claims 1 to 13, wherein said musculoskeletal degenerative disease is a muscular dystrophy.
15. 15. The drug or drug combination for use according to claim 14, wherein the musculoskeletal degenerative disease is Duchenne muscular dystrophy (DMD).
16. The agent or combination of agents for use according to any one of claims 1 to 15, wherein the subject has a phagocytic disorder.
17. 1. An agent which is cilnidipine or a pharmacologically acceptable salt or solvate thereof for use in a method for treating a subject having Duchenne muscular dystrophy (DMD).
18. 18. The method of claim 17, wherein the method comprises administering an effective amount of the agent to reduce creatine kinase (CK) and / or lactose dehydrogenase (LDH) in the plasma of the subject.
19. A phagocytosis activator for use in the manufacture of a medicament for treating a musculoskeletal degenerative disease.
